Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 18Specimen Handling 16Magnetic Resonance Spectroscopy 11Biopsy 11Paclitaxel 8Carboplatin 8trastuzumab deruxtecan 6Pemetrexed 6Nivolumab 6Irinotecan 6Fulvestrant 6Bevacizumab 6Radiosurgery 5Leucovorin 5Gemcitabine 5Fluorouracil 5Cetuximab 5palbociclib 4Oxaliplatin 4Letrozole 4Cisplatin 4olaparib 3durvalumab 3Taxes 3Ipilimumab 3Docetaxel 3Capecitabine 3130-nm albumin-bound paclitaxel 3sacituzumab govitecan 2ribociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × ceritinib × 30 days × Clear all
NCT02321501 2026-05-20

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
37 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡